查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1970921

流感診斷市場－全球產業規模、佔有率、趨勢、機會、預測：按檢測類型、最終用戶、地區和競爭格局分類，2021-2031年

Influenza Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By End user, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球流感診斷市場預計將從 2025 年的 23.2 億美元成長到 2031 年的 34.9 億美元，複合年成長率為 7.05%。

此領域涵蓋專門的醫療設備和檢測方法，例如分子檢測和快速免疫檢測，旨在識別呼吸道檢體中的遺傳物質和病毒抗原。主要成長要素包括全球季節性流感發病率的上升，以及對準確、早期檢測的迫切需求，以便及時進行治療性介入和控制感染。此外，老年人口的成長需要定期進行健康監測，以及分散式醫療環境中對快速診斷解決方案的偏好不斷成長，也推動了市場擴張。根據美國疾病管制與預防中心 (CDC) 統計，在 2024-2025 年流感季，臨床檢查室處理了約 390 萬份與流感相關的呼吸道檢體，凸顯了龐大的檢測量，從而滿足了市場需求。

市場概覽
預測期 2027-2031
市場規模：2025年 23.2億美元
市場規模：2031年 34.9億美元
複合年成長率：2026-2031年 7.05%
成長最快的細分市場 分子診斷檢測
最大的市場 北美洲

儘管成長要素強勁，但由於先進分子診斷平台的高成本，市場仍面臨許多障礙，阻礙了資源匱乏地區的普及。此外，不均衡的報銷機制以及低成本快速檢測的靈敏度差異，往往會加劇這些經濟障礙。這些限制因素可能導致臨床實務中的猶豫，並阻礙成本敏感型經濟體的市場滲透。

市場促進因素

季節性流感和流行性流感病毒株的全球傳播將成為市場的主要催化劑，需要大量的診斷試劑來最佳化患者照護並控制感染傳播。病毒的持續變異以及疫情後呼吸道病原體的再次出現將加重疾病負擔，因此醫療系統必須提高警覺。例如，2023-2024 年流感季的發生率顯著上升。美國疾病管制與預防中心 (CDC) 在 2024 年 11 月發布的《2023-2024 年流感季總結》中報告稱，美國估計有 4,000 萬例流感病例、47 萬例住院病例和 2.8 萬例死亡病例。這種成長趨勢是全球面臨的挑戰，也是推動市場發展的動力。根據歐洲疾病預防控制中心 (ECDC) 2024 年 11 月發布的《季節性流感 - 2023/2024 年流行病學報告》所證實，2023 年底，巡邏醫療機構的流感陽性率達到峰值 39%，推高了全球診斷耗材的消耗量。

同時，分散式醫療機構對即時臨床決策的需求推動了對快速床邊檢測 (POC) 解決方案的激增。醫療機構正在擴大快速分子檢測和症候群檢測組合的應用，這些檢測可在數分鐘內提供準確結果，從而加快抗病毒治療並提高患者處理效率。這種向分散式診斷的轉變已獲得顯著的商業性成功支持。生物梅里埃公司於 2024 年 9 月發布的「2024 會計年度上半年」報告顯示，受快速解決方案的吸引力和安裝量增加的推動，BIOFIRE 呼吸道檢測組合在第二季度的銷售額成長了 17%。這一趨勢反映了市場結構性轉變，即速度、便利性和靈敏度在呼吸道感染疾病管理中變得越來越重要。

市場挑戰

先進分子診斷平台的高昂成本是全球流感診斷市場成長的主要障礙，尤其是在資源匱乏的經濟體。雖然分子檢測的靈敏度高於快速免疫測定，但這些先進系統所需的大量資本投入和營運成本有效地阻礙了它們在許多開發中國家和分散化地區的普及。這種經濟差距迫使人們繼續依賴靈敏度不可靠的低成本替代方案，導致臨床結果可靠性下降，醫療機構也不願採用新技術。因此，先進診斷技術在富裕地區已趨於飽和，而龐大的潛在市場因成本限制仍未開發，導致市場擴張分散。

診斷能力的這種差距也體現在近期關於全球準備的產業數據中。 2024年7月，創新診斷基金會（FIND）發布了病原體診斷準備指數，結果顯示，全球對甲型和乙型流感的準備度得分僅為56%，遠低於針對SARS-CoV-2的診斷能力。這一低分錶明，全球大部分醫療基礎設施缺乏有效管理所需的診斷工具，而這項缺陷直接源自於部署精準但昂貴的檢測平台所帶來的經濟挑戰。

市場趨勢

隨著醫療系統日益重視同時識別多種流行呼吸道病原體，多重綜合症檢測的廣泛應用正在改變臨床工作流程。這一趨勢源於臨床需求，即在單一高通量流程中區分甲型流感、乙型流感、呼吸道合胞病毒（RSV）和SARS-CoV-2，從而在病毒爆發高峰期最佳化資源分配和患者管理。監管機構對兼具效率和靈敏度的綜合檢測方案的支持，正在加速從單靶點檢測到多重檢測的轉變。正如2025年2月《BioSpectrum India》報導「賽默飛世爾科技公司獲得分子臨床檢測510(k)批准…」報道，賽默飛世爾科技公司旗下Applied Biosystems TaqPath Select Panel多重檢測方案已獲得FDA批准。此方案可在單一流程中檢測和識別四種病毒靶標，展現了產業向整合診斷的轉型。

此外，晶片實驗室和微流體技術的進步透過在緊湊的自動化晶片中實現複雜的分子處理，正在鞏固市場基礎。這些創新將複雜的實驗室通訊協定小型化，從而能夠在分散式環境中以最少的操作人員參與實現精確的樣品製備和擴增。這些微流體系統應用範圍的快速擴大表明，基於晶片的生態系統在應對波動的診斷負荷方面具有結構性依賴性。近期營運數據已證實了這種擴充性。根據丹納赫公司於2025年1月發布的“2024年第四季及全年財務業績”，其採用先進微流體晶片技術的Sepid GeneXpert系統的全球安裝量已超過6萬套，凸顯了擴充性技術在現代診斷策略中的重要性。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球流感診斷市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依檢測類型（常規診斷檢測、分子診斷檢測）
    • 依最終用戶（醫院、檢驗實驗室等）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美流感診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲流感診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區流感診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲流感診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美流感診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球流感診斷市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Abbott Laboratories Limited
  • Becton, Dickinson and Company
  • Coris BioConcept
  • DiaSorin SpA
  • F. Hoffmann-La Roche Ltd
  • Meridian Bioscience Inc
  • Quidel Corporation
  • Sekisui Diagnostics
  • Thermo Fisher Scientific Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23249

The Global Influenza Diagnostics Market is projected to expand from USD 2.32 Billion in 2025 to USD 3.49 Billion by 2031, registering a CAGR of 7.05%. This sector comprises a specialized array of medical devices and tests, such as molecular assays and rapid immunoassays, engineered to identify genetic material or viral antigens in respiratory samples. Primary growth drivers include the increasing global incidence of seasonal influenza and the urgent need for precise, early detection to enable timely therapeutic intervention and outbreak control. Additionally, market expansion is bolstered by a growing geriatric demographic requiring regular health monitoring and a shifting preference toward rapid diagnostic solutions within decentralized healthcare environments. As reported by the Centers for Disease Control and Prevention, clinical laboratories processed roughly 3.9 million respiratory specimens for influenza during the 2024 to 2025 season, highlighting the significant volume of testing that sustains demand.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.32 Billion
Market Size 2031USD 3.49 Billion
CAGR 2026-20317.05%
Fastest Growing SegmentMolecular Diagnostic Assay
Largest MarketNorth America

Despite these strong growth factors, the market encounters substantial hurdles due to the high costs linked to advanced molecular diagnostic platforms, which limit their uptake in resource-constrained areas. This economic barrier is often exacerbated by uneven reimbursement frameworks and the variable sensitivity associated with lower-cost rapid tests. Such limitations can result in clinical hesitation and hinder wider market penetration in cost-sensitive economies.

Market Driver

The escalating global prevalence of both seasonal and pandemic influenza strains serves as a major market catalyst, requiring high diagnostic volumes to optimize patient care and curb transmission. The persistent mutation of viruses and the resurgence of respiratory pathogens post-pandemic have increased the disease burden, necessitating heightened vigilance from healthcare systems. For example, the 2023-2024 season saw substantial morbidity; the Centers for Disease Control and Prevention reported in November 2024 via the '2023-2024 Influenza Season Summary' that the United States experienced an estimated 40 million flu illnesses, 470,000 hospitalizations, and 28,000 deaths. This rising incidence is a global issue fueling market momentum, as confirmed by the European Centre for Disease Prevention and Control's 'Seasonal influenza - Annual Epidemiological Report for 2023/2024' from November 2024, which noted that positive influenza tests in sentinel primary care peaked at 39% in late 2023, driving global consumption of diagnostic supplies.

Concurrently, there is a surging demand for rapid Point-of-Care (POC) testing solutions, spurred by the vital need for immediate clinical decisions in decentralized locations. Healthcare providers are increasingly adopting rapid molecular assays and syndromic panels that yield accurate results in minutes, thereby facilitating timely antiviral treatment and improved patient throughput. This transition toward decentralized diagnostics is highlighted by significant commercial gains; bioMerieux's 'First-Half 2024 Results' from September 2024 indicated a 17% rise in BIOFIRE respiratory panel sales during the second quarter, driven by the appeal of rapid solutions and a growing installed base. This trend signifies a structural market shift where speed and accessibility are becoming as critical as sensitivity in the management of respiratory outbreaks.

Market Challenge

The substantial cost associated with sophisticated molecular diagnostic platforms represents a major impediment to the growth of the Global Influenza Diagnostics Market, especially within resource-limited economies. Although molecular assays offer higher sensitivity than rapid immunoassays, the considerable capital investment and operational costs required for these advanced systems effectively preclude their use in many developing nations and decentralized settings. This financial inequality necessitates a continued dependence on less expensive alternatives that frequently demonstrate variable sensitivity, resulting in unreliable clinical outcomes and provider reluctance to embrace newer technologies. Consequently, the market experiences fragmented expansion, characterized by saturation of advanced diagnostics in affluent regions while vast potential markets remain underserved due to cost constraints.

This disparity in diagnostic capacity is evident in recent industry data concerning global preparedness. In July 2024, the Foundation for Innovative New Diagnostics (FIND) released the Pathogen Diagnostic Readiness Index, which revealed a global readiness score of merely 56% for Influenza A and Influenza B, a figure that significantly lags behind the capacity built for SARS-CoV-2. This low score suggests that a substantial proportion of global healthcare infrastructure is missing the necessary diagnostic tools for effective management, a shortfall directly attributable to the economic challenges associated with implementing precise yet costly testing platforms.

Market Trends

The widespread implementation of Multiplex Syndromic Testing is transforming clinical workflows as healthcare systems increasingly value the simultaneous identification of co-circulating respiratory pathogens. This movement is fueled by the clinical requirement to differentiate between Influenza A, Influenza B, RSV, and SARS-CoV-2 within a single high-throughput process, which optimizes resource allocation and patient management during peak viral periods. The transition from single-target assays is gaining speed due to regulatory backing for comprehensive panels that provide efficiency while maintaining sensitivity. As reported by BioSpectrum India in February 2025, in the article 'Thermo Fisher announces 510(k) clearance of molecular clinical test...', Thermo Fisher Scientific secured FDA clearance for its Applied Biosystems TaqPath Select Panel, a multiplex solution engineered to detect and distinguish these four viral targets in one workflow, highlighting the industry's shift toward consolidated diagnostic methods.

Furthermore, advancements in Lab-on-a-Chip and Microfluidic Technologies are strengthening market infrastructure by facilitating complex molecular processing inside compact, automated cartridges. These innovations allow for the miniaturization of intricate laboratory protocols, enabling precise sample preparation and amplification in decentralized settings with little need for operator involvement. The rapid growth of the installed base for these microfluidic systems suggests a structural dependence on cartridge-based ecosystems to manage variable testing loads. This scalability is demonstrated by recent operational data; according to Danaher Corporation's 'Fourth Quarter and Full Year 2024 Results' from January 2025, the global installed base for their Cepheid GeneXpert system, which utilizes advanced microfluidic cartridge technology, grew to over 60,000 instruments, underscoring the vital role of scalable technology in contemporary diagnostic strategies.

Key Market Players

  • Abbott Laboratories Limited
  • Becton, Dickinson and Company
  • Coris BioConcept
  • DiaSorin SpA
  • F. Hoffmann-La Roche Ltd
  • Meridian Bioscience Inc
  • Quidel Corporation
  • Sekisui Diagnostics
  • Thermo Fisher Scientific Inc

Report Scope

In this report, the Global Influenza Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Influenza Diagnostics Market, By Test Type

  • Traditional Diagnostic Test
  • Molecular Diagnostic Assay

Influenza Diagnostics Market, By End user

  • Hospital
  • Laboratories
  • Others

Influenza Diagnostics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Influenza Diagnostics Market.

Available Customizations:

Global Influenza Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Influenza Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test Type (Traditional Diagnostic Test, Molecular Diagnostic Assay)
    • 5.2.2. By End user (Hospital, Laboratories, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Influenza Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test Type
    • 6.2.2. By End user
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Influenza Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Test Type
        • 6.3.1.2.2. By End user
    • 6.3.2. Canada Influenza Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Test Type
        • 6.3.2.2.2. By End user
    • 6.3.3. Mexico Influenza Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Test Type
        • 6.3.3.2.2. By End user

7. Europe Influenza Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test Type
    • 7.2.2. By End user
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Influenza Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Test Type
        • 7.3.1.2.2. By End user
    • 7.3.2. France Influenza Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Test Type
        • 7.3.2.2.2. By End user
    • 7.3.3. United Kingdom Influenza Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Test Type
        • 7.3.3.2.2. By End user
    • 7.3.4. Italy Influenza Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Test Type
        • 7.3.4.2.2. By End user
    • 7.3.5. Spain Influenza Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Test Type
        • 7.3.5.2.2. By End user

8. Asia Pacific Influenza Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test Type
    • 8.2.2. By End user
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Influenza Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Test Type
        • 8.3.1.2.2. By End user
    • 8.3.2. India Influenza Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Test Type
        • 8.3.2.2.2. By End user
    • 8.3.3. Japan Influenza Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Test Type
        • 8.3.3.2.2. By End user
    • 8.3.4. South Korea Influenza Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Test Type
        • 8.3.4.2.2. By End user
    • 8.3.5. Australia Influenza Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Test Type
        • 8.3.5.2.2. By End user

9. Middle East & Africa Influenza Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test Type
    • 9.2.2. By End user
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Influenza Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Test Type
        • 9.3.1.2.2. By End user
    • 9.3.2. UAE Influenza Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Test Type
        • 9.3.2.2.2. By End user
    • 9.3.3. South Africa Influenza Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Test Type
        • 9.3.3.2.2. By End user

10. South America Influenza Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Test Type
    • 10.2.2. By End user
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Influenza Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Test Type
        • 10.3.1.2.2. By End user
    • 10.3.2. Colombia Influenza Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Test Type
        • 10.3.2.2.2. By End user
    • 10.3.3. Argentina Influenza Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Test Type
        • 10.3.3.2.2. By End user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Influenza Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott Laboratories Limited
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Becton, Dickinson and Company
  • 15.3. Coris BioConcept
  • 15.4. DiaSorin SpA
  • 15.5. F. Hoffmann-La Roche Ltd
  • 15.6. Meridian Bioscience Inc
  • 15.7. Quidel Corporation
  • 15.8. Sekisui Diagnostics
  • 15.9. Thermo Fisher Scientific Inc

16. Strategic Recommendations

17. About Us & Disclaimer